Equity Research, Broker Reports, and media content on Novo Nordisk A/S Class B

  • Access the latest forecasts, broker valuations, multiples, and video content from the city about Novo Nordisk A/S Class B
  • See live updates from analysts, company announcements, and other news in a personalised/single dashboard

Novo Nordisk A/S Class B

Company Profile

Research, Charts & Company Announcements

Research Tree provides access to ongoing research coverage, media content and regulatory news on Novo Nordisk A/S Class B. We currently have 1 research reports from 5 professional analysts.

Date Source Announcement
03May19 06:30 GNW Novo Nordisk's operating profit increased by 14% in Danish kroner and by 8% at constant exchange rates (CER) in the first three months of 2019
26Apr19 15:46 GNW Novo Nordisk receives positive opinion from the European regulatory authorities for Esperoct® (turoctocog alfa pegol, N8-GP) for the treatment of haemophilia A
26Apr19 09:58 GNW Novo Nordisk files for EU regulatory approval of oral semaglutide for the treatment of type 2 diabetes
24Apr19 17:27 GNW Novo Nordisk A/S - Reduction of the share capital
21Mar19 14:58 GNW Resolutions from the Annual General Meeting of Novo Nordisk A/S
20Mar19 14:00 GNW Novo Nordisk files oral semaglutide for US regulatory approval of glycaemic control, as well as for CV risk reduction for oral semaglutide and Ozempic®
18Mar19 11:02 GNW Novo Nordisk settles US patent litigation case on Victoza® (liraglutide) with Teva
  • Frequency of research reports

     

  • Research reports on

    Novo Nordisk A/S Class B

  • Providers covering

    Novo Nordisk A/S Class B